BMEZ

BlackRock Health Sciences Term Trust will conduct a tender offer for up to 5% of its shares at 98% of NAV, expected to run from October 16 to November 18, 2026. The tender triggered automatically because BMEZ's average discount over the nine months ended September 30 was -11.05%, wider than the program's -10% threshold. At a -10.42% discount (October 12 close), tendering captures about 9.4% of alpha per accepted share, but only about 10% of tendered shares would be accepted at 50% participation.

CEFs fell this week: 4 of 26 sectors rose on price (average -1.01%) and 1 of 26 on NAV (average -0.95%). IAE and IHD stop trading on October 13 and will reorganize at NAV into an open-end Voya fund. BMEZ's discount management program triggered a tender offer for 5% of its shares at 98% of NAV, expected to run from October 16 to November 18.

BlackRock Health Sciences Trust II offers a balanced biotech and pharma portfolio, with top holdings showing strong FCF margins and positive growth. BMEZ trades at a notable -10% NAV discount, presenting an attractive entry point as sector rotation into healthcare gains momentum. I expect healthcare to outperform through 2026, driven by lower valuations, technological innovation, and defensive positioning during midterm election cycles.

BlackRock Health Sciences Trust II offers exposure to healthcare innovation but faces NAV instability and dividend sustainability concerns. BMEZ's strategy targets high-growth healthcare sectors, leveraging BlackRock's expertise, yet recent performance highlights volatility and risk to distributions. Potential growth in healthcare is supported by industry trends, but BMEZ's NAV fluctuations and payout risks warrant close monitoring.